Crystalys was co-founded by the Executive Team, Catalys Pacific and Novo Holdings, organizations with extensive experience supporting the development and growth of biotechnology companies. The company’s leadership team brings deep expertise in drug development, clinical research, and global regulatory strategy.
Crystalys is focused on advancing innovative therapies that address the unmet needs of patients with gout while continuing to build a company grounded in scientific rigor and clinical excellence.
upcoming events
- UBS Private Biotech Innovation Summit, New York – May 18
- RBC Global Healthcare Conference, New York – May 19-20
- Jefferies Global Healthcare conference, New York – June 2-4
- EULAR, London – June 3-6, 2026
Crystalys Therapeutics was co-founded by Catalys Pacific and Novo Holdings